SmartHealth Catalyzer — Full Portfolio
10 tracked investments · listed companies and verified rows first
Focuses on gastrointestinal disease treatment and prevention by restoring the GI mucosal-immune system with a first-in-class therapeutic.
BiotechIllinois, US
Joseph Francis Pierre(Director)Brian Yoor(Director)Eugene Chang(Director)Jaime Contreras(Director)John C. Alverdy(Director)Peter Farmakis(Executive Officer, Director)
32 Biosciences develops gut mucosal-immune science to prevent and treat gastrointestinal diseases, offering a GI discovery platform that measures metabolomic signatures of the gut mucosal-immune system and a therapeutic platform based on a Mucosal Immune Modulator (MIM) that restores and protects the gastrointestinal mucosal-immune barrier.
BiotechDigital Health
Created a point-of-care diagnostic platform for specialty physician and oncologist offices enabling rapid cancer diagnosis during patient visits.
Developing a first-in-class smartlens system for glaucoma treatment that rapidly reduces intraocular pressure in patients.
Co-investorsElevate Ventures
Cadenza Bio develops small-molecule drugs for oral administration to treat demyelinating and inflammatory diseases.
BiotechFemTechMedical DevicesYukon, US
Carol Curtis, PhD(Chief Executive Officer, Founder)Elaine Hamm, PhD(Chief Operating Officer, Founder)John Katzenellenbogen, PhD(Scientific Founder)Seema Tiwari-Woodruff, PhD(Scientific Founder)Elaine Hamm(Executive Officer, Director)Carol Curtis(Executive Officer, Director)
Co-investorsCortado VenturesIllinois VenturesPlains Ventures
Saros is a biopharmaceutical company developing immunotherapies based on a proprietary lipid nanoparticle platform that targets innate immune cells to activate immune responses.
BiotechHealthtech
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.